UTulsa’s Hurricane Ventures announces investments in Percipio Health, Prelude
TULSA, Okla., March 6, 2025 /PRNewswire/ -- The University of Tulsa and Hurricane Ventures have announced two new start-up investments:...
Brain
Adaptive Sound Technologies, Inc. (ASTI) launches their gamma sound and light therapy device, the SOUND+THERAPY, on Walmart.com and Amazon.com
SOUND+THERAPY is a bedside device that uses 40 Hertz gamma sound beats and light flashes to promote better sleep. Studies...
FACIT and OBIO® announce inaugural WeSEED cohort of women-led start-ups in joint seed capital and commercialization program
Program supports women entrepreneurs in life science who are driving the advancement of innovations and healthcare TORONTO, March 6, 2025...
Lindus Health and Tiefenbacher Group Launching Clinical Trial to Advance ME/CFS Research and Treatment
BOSTON, March 6, 2025 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials, and Tiefenbacher Group, a leading...
St. Baldrick’s Foundation Awards $1.4 Million in Fellowships to Advance Childhood Cancer Research
Los Angeles, California--(Newsfile Corp. - March 6, 2025) - The St. Baldrick's Foundation, the largest charity funder of childhood cancer...
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study...
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025
SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...
Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment...
Linus Health Achieves Landmark Research Recognition Across Peer-Reviewed Medical and Scientific Journals
Research validates the efficacy and accuracy of its digital solutions designed to detect early indicators of cognitive impairment BOSTON, March...
NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a...
Business Plan Contest “Photonics Challenge 2025” was Successfully Held in Hamamatsu City, the Center of the Optical Industry
Three companies with outstanding optical technology – Beyond Optical Medical Technologies, Ectobrain Devices and Catana Corporation – presented groundbreaking ideas and...
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily...
ABM of PPC Inc. Unveils the World’s First Emotion Processing Unit (EPU) Chip: A 10 Trillion dollar Industry Disruptor Transforming Neuroscience, Mental Health, Military Strategy & Human Performance
Boston, March 3, 2025 /PRNewswire/ -- Advanced Brain Methodologies Inc. (ABM) a division of Primary & Preventive Care Inc., has...
Protega Pharmaceuticals collaborates with Wellgistics Health to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™
ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond™, is designed to provide multiple levels of protection PRINCETON, N.J., March 3, 2025...
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids,...
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule...
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
NKGen explores the use of troculeucel as a potential treatment option for post-stroke patients.SANTA ANA, Calif., March 03, 2025 (GLOBE...
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting...
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025License agreement...